Trial Profile
Sirolimus in Conjunction With EYLEA (Aflibercept) Versus EYLEA Alone for Exudative AMD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 18 Apr 2017 Status changed from active, no longer recruiting to completed.
- 19 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2016 New trial record